Revenue soared almost one fifth to $44.4 billion, thanks to a strong contribution from oncology or cancer treatments that offset sliding fourth-quarter sales of its COVID vaccine. COVID-19 medicine sales are expected to decline "significantly" in 2023 with "minimal revenue" from COVID jab Vaxzevria, it cautioned.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/c406Ylt
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» AstraZeneca profits soar on cancer drugs, Alexion buy
https://ift.tt/7OBaoSJ
No comments:
Post a Comment